Pozen's $25 million Vimovo milestone to fund integrated aspirin portfolio
This article was originally published in Scrip
Pozen says that the $25 million milestone payment that it recently received from AstraZeneca following marketing and pricing approval for Vimovo (naproxen/ esomeprazole magnesium) in the UK will fund the development of its integrated aspirin therapies, which it refers to as its PA pipeline.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.